Giuliana Mombelli1, Raffaella Bosisio2, Laura Calabresi3, Paolo Magni3, Chiara Pavanello2, Franco Pazzucconi3, Cesare R Sirtori4. 1. Dipartimento Cardiotoracovascolare, A.O. Ospedale Niguarda Cà Granda, Milano, Italy. Electronic address: giuliana.mombelli@ospedaleniguarda.it. 2. Dipartimento Cardiotoracovascolare, A.O. Ospedale Niguarda Cà Granda, Milano, Italy. 3. Department of Pharmacological Sciences, Università degli Studi di Milano, 20133 Milano, Italy. 4. Dipartimento Cardiotoracovascolare, A.O. Ospedale Niguarda Cà Granda, Milano, Italy; Department of Pharmacological Sciences, Università degli Studi di Milano, 20133 Milano, Italy.
Abstract
BACKGROUND: Cardiovascular risk in men rises around the fourth decade of life, whereas women appear to be protected by sex hormones until menopause. This, in turn, tends to negatively affect the lipid profile. Since the 1980s, the incidence of cardiovascular diseases has been reported to progressively decline in men, but it has persisted almost unchanged in women. Major clinical trials on statins have been mostly conducted in men and have fostered the introduction of these agents into clinical practice worldwide. However, only few reports have examined a possible differential activity of statins in the 2 genders, providing in some cases opposite findings. OBJECTIVE: To evaluate gender-related differences in statin responses. METHODS: Variations of lipid profile after 1-year of treatment with different statins in 337 dyslipidemic patients (171 men and 166 women). RESULTS: In this series of patients, a significantly attenuated reduction of total cholesterol and low-density lipoprotein cholesterol in women vs men on drug treatment was noted after adjustment for dose and statin power (low-density lipoprotein cholesterol: -28.5 ± 11.8% in men vs -22.7 ± 11.8% in women; P < .001). CONCLUSIONS: The present study indicates that statin treatment has a reduced effectiveness in improving the plasma lipid profile in dyslipidemic women vs men. Whether such gender-related differences may have an impact on clinical outcomes remains to be elucidated.
BACKGROUND: Cardiovascular risk in men rises around the fourth decade of life, whereas women appear to be protected by sex hormones until menopause. This, in turn, tends to negatively affect the lipid profile. Since the 1980s, the incidence of cardiovascular diseases has been reported to progressively decline in men, but it has persisted almost unchanged in women. Major clinical trials on statins have been mostly conducted in men and have fostered the introduction of these agents into clinical practice worldwide. However, only few reports have examined a possible differential activity of statins in the 2 genders, providing in some cases opposite findings. OBJECTIVE: To evaluate gender-related differences in statin responses. METHODS: Variations of lipid profile after 1-year of treatment with different statins in 337 dyslipidemic patients (171 men and 166 women). RESULTS: In this series of patients, a significantly attenuated reduction of total cholesterol and low-density lipoprotein cholesterol in women vs men on drug treatment was noted after adjustment for dose and statin power (low-density lipoprotein cholesterol: -28.5 ± 11.8% in men vs -22.7 ± 11.8% in women; P < .001). CONCLUSIONS: The present study indicates that statin treatment has a reduced effectiveness in improving the plasma lipid profile in dyslipidemic women vs men. Whether such gender-related differences may have an impact on clinical outcomes remains to be elucidated.
Authors: Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham Journal: Hear Res Date: 2020-02-06 Impact factor: 3.208
Authors: Stefania Cicolari; Chiara Pavanello; Elena Olmastroni; Marina Del Puppo; Marco Bertolotti; Giuliana Mombelli; Alberico L Catapano; Laura Calabresi; Paolo Magni Journal: Nutrients Date: 2021-01-28 Impact factor: 5.717
Authors: Amy S Etheridge; Paul J Gallins; Dereje Jima; K Alaine Broadaway; Mark J Ratain; Erin Schuetz; Eric Schadt; Adrian Schroder; Cliona Molony; Yihui Zhou; Karen L Mohlke; Fred A Wright; Federico Innocenti Journal: Clin Pharmacol Ther Date: 2020-01-30 Impact factor: 6.875